Dr Lal Pathlabs

Healthcare stocks in long runway for growth; HDFC Securities initiates with ‘Buy’ on Apollo Hospitals, Medplus Health

by
Healthcare stocks in long runway for growth; HDFC Securities initiates with ‘Buy’ on Apollo Hospitals, Medplus Health

The industry saw some growth impact during COVID in FY21 as it grew 10% YoY to ₹8 lakh crore and subsequently a bounce-back in FY22, growing 15% YoY to ₹9.2 lakh crore, and normalized growth in FY23 at 15% YoY to ₹10 lakh crore. Going ahead, key structural drivers such as an ageing population, an … Read more

Dr Lal Pathlabs, Metropolis shares gain on Kotak Equities’ rating upgrades, target price raise

by
Dr Lal Pathlabs, Metropolis shares gain on Kotak Equities' rating upgrades, target price raise

After a long stretch of stock underperformance, domestic brokerage Kotak Institutional Equities stated in its most recent report that it has double upgraded Dr Lal Pathlabs from Sell to Add with an increased fair value of ₹2,360. Given reasonable prices, the brokerage has also increased Metropolis Healthcare’s fair value to ₹1,600, keeping its Reduce rating. Following … Read more